Alf Nicklasson - Basilea Pharmaceutica Member of the Board of Directors
| BPMUF Stock | USD 44.45 3.70 9.08% |
Director
Dr. Alf Gunnar Martin Nicklasson, Ph.D., was Member of the Board of Directors of Basilea Pharmaceutica Ltd since April 21, 2016. Prior to that, he was Chairman of the Board of Directors of the Company from 2013. He is Chairman of the Compensation Committee and Member of the Audit Committee at the Company. Dr. Nicklasson is a Honorary Associate Professor at the Pharmaceutical Faculty, University of Uppsala since 1985. From 2007 to 2010, Dr. Nicklasson served as president and chief executive officer of Biovitrum AB and Swedish Orphan Biovitrum AB. From 1999 to 2007 he held various executive vice president positions at AstraZeneca Plc., and acted as a member of the Executive Committee. Dr. Nicklasson is member of the board of Biocrine AB and chairman of the board of directors of Kymab Group Ltd., Orexo AB and Zealand Pharma AS . He also serves as a consultant at Excore Consulting KB in Sweden since 2016.
| Age | 63 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 41 61 606 11 11 |
| Web | https://www.basilea.com |
Basilea Pharmaceutica Management Efficiency
The company has return on total asset (ROA) of 0.0261 % which means that it generated a profit of $0.0261 on every $100 spent on assets. This is way below average. Basilea Pharmaceutica's management efficiency ratios could be used to measure how well Basilea Pharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ian Brindle | Covalon Technologies | N/A | |
| Donald Oborowsky | Ceapro Inc | N/A | |
| John Hands | Covalon Technologies | N/A | |
| John Zupancic | Ceapro Inc | N/A | |
| Ronald Smith | Covalon Technologies | 66 | |
| John Suk | Covalon Technologies | N/A | |
| Jeffrey Mandel | Covalon Technologies | N/A | |
| Joseph Cordiano | Covalon Technologies | N/A | |
| Murray Miller | Covalon Technologies | N/A | |
| Elinor Caplan | Covalon Technologies | N/A | |
| Glenn Rourke | Ceapro Inc | N/A | |
| Gale Pollock | Covalon Technologies | N/A | |
| William Li | Ceapro Inc | 49 | |
| Martin Bernholtz | Covalon Technologies | N/A | |
| Myrna Francis | Covalon Technologies | N/A | |
| Ulrich Kosciessa | Ceapro Inc | N/A | |
Management Performance
| Return On Asset | 0.0261 |
Basilea Pharmaceutica Leadership Team
Elected by the shareholders, the Basilea Pharmaceutica's board of directors comprises two types of representatives: Basilea Pharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Basilea. The board's role is to monitor Basilea Pharmaceutica's management team and ensure that shareholders' interests are well served. Basilea Pharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Basilea Pharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Rinderknecht, Member of the Board of Directors | ||
| Marc Engelhardt, Member of the Management, Chief Medical Officer | ||
| Martin Nicklasson, Chairman of the Board of Directors | ||
| Domenico Scala, Member of the Board of Directors | ||
| Guenter Ditzinger, CTO, Member of the Management Committee | ||
| Marc MD, Chief Officer | ||
| Barbara Zink, Head - Corporate Development | ||
| Nicole Onetto, Member of the Board of Directors | ||
| Heidi McDaid, Head of Global HR | ||
| Peer Schroder, Head Relations | ||
| Ingrid HeinzeKrauss, Member of the Management Committee, CTO | ||
| Dietrich Stber, Head Services | ||
| HansBeat Guertler, Member of the Board of Directors | ||
| Peer Schroeder, Head of Corporate Communications & Investor Relations | ||
| Lutz Wevelsiep, Head Affairs | ||
| Daniel Lew, Member of the Board of Directors | ||
| David Veitch, Chief Commercial Officer, Member of the Management Committee | ||
| Ursula Eberhardt, Head HR | ||
| Donato Spota, CFO | ||
| Achim Kaufhold, Member of the Management Committee, Chief Medical Officer | ||
| Ronald Scott, CEO | ||
| Alf Nicklasson, Member of the Board of Directors | ||
| Adesh Kaul, Chief Officer | ||
| Damian Heller, Gen Sec | ||
| Gerrit Hauck, Chief Officer | ||
| Anne Stehlin, Member of the Management Board, Head of Global Quality Management | ||
| Thomas Werner, Member of the Board of Directors | ||
| Laurenz Kellenberger, Chief Scientific Officer | ||
| Steven Skolsky, Member of the Board of Directors |
Basilea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Basilea Pharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 724.26 M | |||
| Shares Outstanding | 11.93 M | |||
| Shares Owned By Insiders | 3.07 % | |||
| Shares Owned By Institutions | 29.13 % | |||
| Price To Earning | 200.00 X | |||
| Price To Sales | 4.09 X | |||
| Revenue | 148.12 M |
Pair Trading with Basilea Pharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Basilea Pharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Basilea Pharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving against Basilea Pink Sheet
| 0.74 | CSLLY | CSL | PairCorr |
| 0.66 | CMXHF | CSL Limited | PairCorr |
| 0.57 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.53 | ZTLLF | Zonetail | PairCorr |
The ability to find closely correlated positions to Basilea Pharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Basilea Pharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Basilea Pharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Basilea Pharmaceutica AG to buy it.
The correlation of Basilea Pharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Basilea Pharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Basilea Pharmaceutica moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Basilea Pharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Basilea Pharmaceutica AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Basilea Pink Sheet analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |